{"id":355367,"date":"2026-11-19T14:42:14","date_gmt":"2026-11-19T09:12:14","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=355367"},"modified":"2026-11-19T14:42:14","modified_gmt":"2026-11-19T09:12:14","slug":"oncology-medicines-firm-fluorochemicals-producer-and-hospital-software-provider-stocks-roadmap-wetland-list","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/oncology-medicines-firm-fluorochemicals-producer-and-hospital-software-provider-stocks-roadmap-wetland-list\/","title":{"rendered":"3 Oncology Medicines Firm, Fluorochemicals Producer and Hospital Software Provider Stocks With a Strong Future Roadmap: Natco Pharma, Navin Fluorine International and Inventurus Knowledge Solutions"},"content":{"rendered":"<p style=\"border-left:4px solid #1F4E84;background:#EBF3FB;padding:10px 16px;font-style:italic;\"><em>Natco Pharma, Navin Fluorine International and Inventurus Knowledge Solutions: ROE of 15.4% to 25.8% and FY22 to FY26 revenue CAGR of 21.0% to 42.2%. Prices as of 18 Nov 2026.<\/em><\/p>\n<div style=\"background:#F0F9FF;border-left:4px solid #2E7D32;border-radius:6px;padding:14px 18px;margin:18px 0;\">\n<p style=\"margin:0;color:#1F4E84;font-size:14px;\"><strong>Quick Answer<\/strong><\/p>\n<p style=\"margin:8px 0 0;\">The three <strong>cancer drug, fluorine and health IT stocks<\/strong> to watch are <strong>Natco Pharma<\/strong>, <strong>Navin Fluorine International<\/strong> and <strong>Inventurus Knowledge Solutions<\/strong>. Their <strong>return on equity<\/strong> ranges from <strong>15.4% to 25.8%<\/strong>, and their <strong>revenue compound annual growth<\/strong> from FY22 to FY26 ranges from 21.0% to 42.2%. Inventurus Knowledge Solutions leads on both return on equity at 25.8% and revenue growth at 42.2% a year. Prices are based on the 18 November 2026 close, and this article is educational, not investment advice.<\/p>\n<\/div>\n<p>Cancer drug, fluorine and health IT stocks let investors follow companies that serve a growing part of the Indian economy. Natco Pharma, Navin Fluorine International and Inventurus Knowledge Solutions cover a specialty drugs maker, a fluorine chemicals maker and a healthcare IT services company.<\/p>\n<p>This list covers three cancer drug, fluorine and health IT stocks with complete current figures: Natco Pharma, Navin Fluorine International and Inventurus Knowledge Solutions. Every figure comes from the latest reported financials and the 18 November 2026 market close. Companies without complete current figures were left out.<\/p>\n<p style=\"margin-top:24px;\"><strong><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&#038;utm_medium=oncology-medicines-firm-fluorochemicals-producer-and-hospital-software-provider-stocks-roadmap-wetland-list\">Click Here &#8211; Get Free Investment Predictions<\/a><\/strong><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/oncology-medicines-firm-fluorochemicals-producer-and-hospital-software-provider-stocks-roadmap-wetland-list\/#What_Are_Cancer_Drug_Fluorine_and_Health_IT_Stocks\" title=\"What Are Cancer Drug, Fluorine and Health IT Stocks?\">What Are Cancer Drug, Fluorine and Health IT Stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/oncology-medicines-firm-fluorochemicals-producer-and-hospital-software-provider-stocks-roadmap-wetland-list\/#Cancer_Drug_Fluorine_and_Health_IT_Stocks_at_a_Glance\" title=\"Cancer Drug, Fluorine and Health IT Stocks at a Glance\">Cancer Drug, Fluorine and Health IT Stocks at a Glance<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/oncology-medicines-firm-fluorochemicals-producer-and-hospital-software-provider-stocks-roadmap-wetland-list\/#Why_Do_Cancer_Drug_Fluorine_and_Health_IT_Stocks_Have_a_Strong_Roadmap_in_India\" title=\"Why Do Cancer Drug, Fluorine and Health IT Stocks Have a Strong Roadmap in India?\">Why Do Cancer Drug, Fluorine and Health IT Stocks Have a Strong Roadmap in India?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/oncology-medicines-firm-fluorochemicals-producer-and-hospital-software-provider-stocks-roadmap-wetland-list\/#Why_Natco_Pharma_Features_Among_These_Cancer_Drug_Fluorine_and_Health_IT_Stocks\" title=\"Why Natco Pharma Features Among These Cancer Drug, Fluorine and Health IT Stocks\">Why Natco Pharma Features Among These Cancer Drug, Fluorine and Health IT Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/oncology-medicines-firm-fluorochemicals-producer-and-hospital-software-provider-stocks-roadmap-wetland-list\/#Why_Navin_Fluorine_International_Features_Among_These_Cancer_Drug_Fluorine_and_Health_IT_Stocks\" title=\"Why Navin Fluorine International Features Among These Cancer Drug, Fluorine and Health IT Stocks\">Why Navin Fluorine International Features Among These Cancer Drug, Fluorine and Health IT Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/oncology-medicines-firm-fluorochemicals-producer-and-hospital-software-provider-stocks-roadmap-wetland-list\/#Why_Inventurus_Knowledge_Solutions_Features_Among_These_Cancer_Drug_Fluorine_and_Health_IT_Stocks\" title=\"Why Inventurus Knowledge Solutions Features Among These Cancer Drug, Fluorine and Health IT Stocks\">Why Inventurus Knowledge Solutions Features Among These Cancer Drug, Fluorine and Health IT Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/oncology-medicines-firm-fluorochemicals-producer-and-hospital-software-provider-stocks-roadmap-wetland-list\/#Natco_Pharma_vs_Navin_Fluorine_International_vs_Inventurus_Knowledge_Solutions_on_Key_Financials\" title=\"Natco Pharma vs Navin Fluorine International vs Inventurus Knowledge Solutions on Key Financials\">Natco Pharma vs Navin Fluorine International vs Inventurus Knowledge Solutions on Key Financials<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/oncology-medicines-firm-fluorochemicals-producer-and-hospital-software-provider-stocks-roadmap-wetland-list\/#Key_Risks_to_Check_Before_Investing_in_Cancer_Drug_Fluorine_and_Health_IT_Stocks\" title=\"Key Risks to Check Before Investing in Cancer Drug, Fluorine and Health IT Stocks\">Key Risks to Check Before Investing in Cancer Drug, Fluorine and Health IT Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/oncology-medicines-firm-fluorochemicals-producer-and-hospital-software-provider-stocks-roadmap-wetland-list\/#Final_Thoughts_on_Cancer_Drug_Fluorine_and_Health_IT_Stocks\" title=\"Final Thoughts on Cancer Drug, Fluorine and Health IT Stocks\">Final Thoughts on Cancer Drug, Fluorine and Health IT Stocks<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/oncology-medicines-firm-fluorochemicals-producer-and-hospital-software-provider-stocks-roadmap-wetland-list\/#What_are_cancer_drug_fluorine_and_health_IT_stocks\" title=\"What are cancer drug, fluorine and health IT stocks?\">What are cancer drug, fluorine and health IT stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/oncology-medicines-firm-fluorochemicals-producer-and-hospital-software-provider-stocks-roadmap-wetland-list\/#Which_cancer_drug_fluorine_and_health_IT_stocks_are_covered_in_this_list\" title=\"Which cancer drug, fluorine and health IT stocks are covered in this list?\">Which cancer drug, fluorine and health IT stocks are covered in this list?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/oncology-medicines-firm-fluorochemicals-producer-and-hospital-software-provider-stocks-roadmap-wetland-list\/#Why_do_cancer_drug_fluorine_and_health_IT_stocks_have_a_strong_future_roadmap_in_India\" title=\"Why do cancer drug, fluorine and health IT stocks have a strong future roadmap in India?\">Why do cancer drug, fluorine and health IT stocks have a strong future roadmap in India?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/oncology-medicines-firm-fluorochemicals-producer-and-hospital-software-provider-stocks-roadmap-wetland-list\/#How_has_Natco_Pharma_performed_financially\" title=\"How has Natco Pharma performed financially?\">How has Natco Pharma performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/oncology-medicines-firm-fluorochemicals-producer-and-hospital-software-provider-stocks-roadmap-wetland-list\/#How_has_Navin_Fluorine_International_performed_financially\" title=\"How has Navin Fluorine International performed financially?\">How has Navin Fluorine International performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/oncology-medicines-firm-fluorochemicals-producer-and-hospital-software-provider-stocks-roadmap-wetland-list\/#How_has_Inventurus_Knowledge_Solutions_performed_financially\" title=\"How has Inventurus Knowledge Solutions performed financially?\">How has Inventurus Knowledge Solutions performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/oncology-medicines-firm-fluorochemicals-producer-and-hospital-software-provider-stocks-roadmap-wetland-list\/#What_risks_should_investors_check_before_buying_cancer_drug_fluorine_and_health_IT_stocks\" title=\"What risks should investors check before buying cancer drug, fluorine and health IT stocks?\">What risks should investors check before buying cancer drug, fluorine and health IT stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/oncology-medicines-firm-fluorochemicals-producer-and-hospital-software-provider-stocks-roadmap-wetland-list\/#Is_this_list_of_cancer_drug_fluorine_and_health_IT_stocks_investment_advice\" title=\"Is this list of cancer drug, fluorine and health IT stocks investment advice?\">Is this list of cancer drug, fluorine and health IT stocks investment advice?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"What_Are_Cancer_Drug_Fluorine_and_Health_IT_Stocks\"><\/span><strong>What Are Cancer Drug, Fluorine and Health IT Stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p><strong>Cancer drug, fluorine and health IT stocks<\/strong> are listed companies that make specialty medicines for cancer and other serious conditions, make fluorine based chemicals for cooling, batteries and drugs, and provide technology and data services to healthcare providers. Their earnings depend on medicine demand, specialty chemical orders and healthcare technology budgets.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Cancer_Drug_Fluorine_and_Health_IT_Stocks_at_a_Glance\"><\/span><strong>Cancer Drug, Fluorine and Health IT Stocks at a Glance<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<div style=\"overflow-x:auto;\">\n<table style=\"border-collapse:collapse;width:100%;\">\n<thead>\n<tr>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Company<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">CMP (Rs)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Market Cap (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">P\/E<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Industry P\/E<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">ROE (%)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">D\/E<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/natcopharm\/natco-pharma-ltd-share-price-today\">Natco Pharma<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">820.6<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">15,708<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">13.7<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">36.0<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">15.4<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.08<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/navinfluor\/navin-fluorine-international-ltd-share-price-today\">Navin Fluorine International<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">10,278<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">41,847<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">53.0<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">35.1<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">16.7<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.32<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/iks\/inventurus-knowledge-so-l-share-price-today\">Inventurus Knowledge Solutions<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,610.1<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">29,242<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">38.3<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">17.6<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">25.8<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.27<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>On valuation, Natco Pharma trades at a <strong>P\/E<\/strong> below the industry P\/E, while Navin Fluorine International and Inventurus Knowledge Solutions trade above it, which reflects the growth the market already expects. Readers comparing cancer drug, fluorine and health IT stocks should look at <strong>return on equity<\/strong> and debt together, since a high return earned with low debt is easier to sustain. With the Q2 FY27 results season close, investors in cancer drug, fluorine and health IT stocks can use the coming numbers to test whether growth is holding.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Do_Cancer_Drug_Fluorine_and_Health_IT_Stocks_Have_a_Strong_Roadmap_in_India\"><\/span><strong>Why Do Cancer Drug, Fluorine and Health IT Stocks Have a Strong Roadmap in India?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p><strong>Cancer drug, fluorine and health IT stocks<\/strong> have a strong roadmap in India because rising demand for advanced medicines, rising demand for fluorine chemicals and wider healthcare digitisation keep widening the market for these companies.<\/p>\n<ul>\n<li><strong>Specialty drugs.<\/strong> Patients need advanced treatments.<\/li>\n<li><strong>Fluorine chemicals.<\/strong> Cooling and battery makers need fluorine inputs.<\/li>\n<li><strong>Healthcare IT.<\/strong> Providers digitise their operations.<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Why_Natco_Pharma_Features_Among_These_Cancer_Drug_Fluorine_and_Health_IT_Stocks\"><\/span><strong>Why Natco Pharma Features Among These Cancer Drug, Fluorine and Health IT Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the cancer drug, fluorine and health IT stocks on this list, Natco Pharma is a Hyderabad-based pharmaceutical company focused on complex generics, oncology, and active ingredients, with a significant presence in the United States and other regulated markets.<\/p>\n<p>Revenue rose from Rs 2,044 crore in FY22 to Rs 4,376 crore in FY26, a compound annual growth rate of 21.0%. Net profit grew from Rs 170 crore in FY22 to Rs 1,372 crore in FY26, which works out to a compound annual growth rate of 68.5%.<\/p>\n<p>The company has a return on equity of 15.4%, a debt to equity ratio of 0.08 and a <strong>market capitalisation<\/strong> of Rs 15,708 crore. The stock trades at a <strong>P\/E<\/strong> of 13.7, below the industry P\/E of 36.0.<\/p>\n<p><strong>Roadmap:<\/strong> The company has a track record of developing difficult-to-make generics and has built a strong position in oncology and specialty drugs. New product launches in regulated markets and investments in research support the pipeline.<\/p>\n<p><strong>What to watch:<\/strong> Check the timing of key product launches in the US and the contribution from new drug approvals.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Navin_Fluorine_International_Features_Among_These_Cancer_Drug_Fluorine_and_Health_IT_Stocks\"><\/span><strong>Why Navin Fluorine International Features Among These Cancer Drug, Fluorine and Health IT Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the oncology generics, refrigerant inputs and hospital software shares on this list, Navin Fluorine International is a specialty fluorine chemicals company that makes refrigerant gases, specialty fluorochemicals, and custom research and manufacturing services for pharma and agrochemical clients.<\/p>\n<p>In the June 2026 quarter, revenue grew 46.1% year on year to Rs 1,080 crore, while net profit rose 107.7% to Rs 243 crore. Revenue rose from Rs 1,493 crore in FY22 to Rs 3,379 crore in FY26, a compound annual growth rate of 22.7%.<\/p>\n<p>Net profit grew from Rs 263 crore in FY22 to Rs 664 crore in FY26, which works out to a compound annual growth rate of 26.0%. The company has a return on equity of 16.7%, a debt to equity ratio of 0.32 and a market capitalisation of Rs 41,847 crore. The stock trades at a P\/E of 53.0, above the industry P\/E of 35.1.<\/p>\n<p><strong>Roadmap:<\/strong> Growth is driven by specialty chemicals, contract manufacturing for global partners and new fluorination capacity. The company has also added capacity for products linked to battery and clean energy applications.<\/p>\n<p><strong>What to watch:<\/strong> Check the ramp-up of new capacity and the share of the contract manufacturing business in revenue.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Inventurus_Knowledge_Solutions_Features_Among_These_Cancer_Drug_Fluorine_and_Health_IT_Stocks\"><\/span><strong>Why Inventurus Knowledge Solutions Features Among These Cancer Drug, Fluorine and Health IT Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the three companies on this list, Inventurus Knowledge Solutions, known as IKS, is a Mumbai-based healthcare technology and services company that supports healthcare providers and payors in the United States with analytics, clinical coding and technology platforms.<\/p>\n<p>The company has a return on equity of 25.8%, a debt to equity ratio of 0.27 and a market capitalisation of Rs 29,242 crore. The stock trades at a P\/E of 38.3, above the industry P\/E of 17.6.<\/p>\n<p>Revenue rose from Rs 784 crore in FY22 to Rs 3,211 crore in FY26, a compound annual growth rate of 42.2%. Net profit grew from Rs 233 crore in FY22 to Rs 722 crore in FY26, which works out to a compound annual growth rate of 32.7%. In the June 2026 quarter, revenue grew 21.0% year on year to Rs 899 crore, while net profit rose 27.8% to Rs 194 crore.<\/p>\n<p><strong>Roadmap:<\/strong> The company is widening its technology-led services for risk adjustment, care coordination and revenue cycle work. Long-term relationships with large healthcare organisations give it recurring demand.<\/p>\n<p><strong>What to watch:<\/strong> Follow client additions, platform adoption and healthcare policy changes in the United States.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Natco_Pharma_vs_Navin_Fluorine_International_vs_Inventurus_Knowledge_Solutions_on_Key_Financials\"><\/span><strong>Natco Pharma vs Navin Fluorine International vs Inventurus Knowledge Solutions on Key Financials<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The table below sets the three cancer drug, fluorine and health IT stocks side by side on revenue, profit and margin, using reported figures.<\/p>\n<div style=\"overflow-x:auto;\">\n<table style=\"border-collapse:collapse;width:100%;\">\n<thead>\n<tr>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Company<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY22 Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Revenue CAGR (FY22-FY26)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Net Profit (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Net Margin<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Natco Pharma<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">2,044<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">4,376<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">21.0%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,372<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">31.4%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Navin Fluorine International<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,493<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">3,379<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">22.7%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">664<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">19.6%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Inventurus Knowledge Solutions<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">784<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">3,211<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">42.2%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">722<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">22.5%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>Inventurus Knowledge Solutions posts the highest return on equity in this group at 25.8%. Natco Pharma has the largest FY26 revenue at Rs 4,376 crore, and Inventurus Knowledge Solutions shows the fastest revenue growth with a 42.2% compound annual rate. A useful habit with <strong>cancer drug, fluorine and health IT stocks<\/strong> is to check each new quarterly result against the capacity plans the company described earlier.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Key_Risks_to_Check_Before_Investing_in_Cancer_Drug_Fluorine_and_Health_IT_Stocks\"><\/span><strong>Key Risks to Check Before Investing in Cancer Drug, Fluorine and Health IT Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Every theme carries risks that deserve a check before any decision. For these cancer drug, fluorine and health IT stocks, the main points are: Long-term oncology generics, refrigerant inputs and hospital software shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.<\/p>\n<ul>\n<li><strong>Regulatory approvals.<\/strong> Plant inspections and approvals can affect supplies.<\/li>\n<li><strong>Raw material and energy costs.<\/strong> Input prices can move margins in chemicals.<\/li>\n<li><strong>Client spending.<\/strong> Technology budgets can vary with global conditions.<\/li>\n<\/ul>\n<p>Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.<\/p>\n<p style=\"margin-top:24px;\"><strong><a href=\"https:\/\/univest.in\/screeners\">Use the Univest Stock Screener<\/a><\/strong> to filter cancer drug, fluorine and health IT stocks by market capitalisation, P\/E, ROE and growth, and build your own shortlist.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Final_Thoughts_on_Cancer_Drug_Fluorine_and_Health_IT_Stocks\"><\/span><strong>Final Thoughts on Cancer Drug, Fluorine and Health IT Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p><strong>Cancer drug, fluorine and health IT stocks<\/strong> reward investors who follow demand trends, order books and margins together. Natco Pharma, Navin Fluorine International and Inventurus Knowledge Solutions each have a clear plan to grow. Based on the 18 November 2026 close, Natco Pharma trades at Rs 820.6, Navin Fluorine International at Rs 10,278 and Inventurus Knowledge Solutions at Rs 1,610.1. Valuation matters as much as growth, so compare each company&#8217;s P\/E with its industry P\/E before adding any of these cancer drug, fluorine and health IT stocks to a watchlist.<\/p>\n<p style=\"margin-top:24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&#038;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track cancer drug, fluorine and health IT stocks, set price alerts and get research-backed stock ideas.<\/em><\/p>\n<div style=\"background:#CC0000;border-radius:8px;padding:16px 20px;margin:24px 0;\">\n<p style=\"color:#FFFFFF;font-size:13px;line-height:1.7;margin:0;\"><strong style=\"color:#FFFFFF;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/div>\n<h3><span class=\"ez-toc-section\" id=\"What_are_cancer_drug_fluorine_and_health_IT_stocks\"><\/span><strong>What are cancer drug, fluorine and health IT stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Cancer drug, fluorine and health IT stocks are listed companies that make specialty medicines for cancer and other serious conditions, make fluorine based chemicals for cooling, batteries and drugs, and provide technology and data services to healthcare providers. Their earnings depend on medicine demand, specialty chemical orders and healthcare technology budgets. This list looks at three of them, Natco Pharma, Navin Fluorine International and Inventurus Knowledge Solutions, using reported FY22 to FY26 financials and the 18 November 2026 closing prices.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Which_cancer_drug_fluorine_and_health_IT_stocks_are_covered_in_this_list\"><\/span><strong>Which cancer drug, fluorine and health IT stocks are covered in this list?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> This list covers Natco Pharma, Navin Fluorine International and Inventurus Knowledge Solutions. Based on the 18 November 2026 close, Natco Pharma traded at Rs 820.6, Navin Fluorine International at Rs 10,278 and Inventurus Knowledge Solutions at Rs 1,610.1. Their return on equity ranges from <strong>15.4% to 25.8%<\/strong>, and their <strong>revenue compound annual growth<\/strong> from FY22 to FY26 ranges from 21.0% to 42.2%.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Why_do_cancer_drug_fluorine_and_health_IT_stocks_have_a_strong_future_roadmap_in_India\"><\/span><strong>Why do cancer drug, fluorine and health IT stocks have a strong future roadmap in India?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> <strong>Cancer drug, fluorine and health IT stocks<\/strong> have a strong roadmap in India because rising demand for advanced medicines, rising demand for fluorine chemicals and wider healthcare digitisation keep widening the market for these companies. The main drivers are as follows. Specialty drugs. Patients need advanced treatments. Fluorine chemicals. Cooling and battery makers need fluorine inputs. Healthcare IT. Providers digitise their operations. Together these factors give the companies on this list a visible path for growth over the coming years.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_Natco_Pharma_performed_financially\"><\/span><strong>How has Natco Pharma performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 2,044 crore in FY22 to Rs 4,376 crore in FY26, a compound annual growth rate of 21.0%. Net profit grew from Rs 170 crore in FY22 to Rs 1,372 crore in FY26, which works out to a compound annual growth rate of 68.5%. The company has a return on equity of 15.4%, a debt to equity ratio of 0.08 and a market capitalisation of Rs 15,708 crore. The stock trades at a P\/E of 13.7, below the industry P\/E of 36.0. Looking ahead, the company has a track record of developing difficult-to-make generics and has built a strong position in oncology and specialty drugs. New product launches in regulated markets and investments in research support the pipeline.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_Navin_Fluorine_International_performed_financially\"><\/span><strong>How has Navin Fluorine International performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 1,493 crore in FY22 to Rs 3,379 crore in FY26, a compound annual growth rate of 22.7%. Net profit grew from Rs 263 crore in FY22 to Rs 664 crore in FY26, which works out to a compound annual growth rate of 26.0%. In the June 2026 quarter, revenue grew 46.1% year on year to Rs 1,080 crore, while net profit rose 107.7% to Rs 243 crore. The company has a return on equity of 16.7%, a debt to equity ratio of 0.32 and a market capitalisation of Rs 41,847 crore. The stock trades at a P\/E of 53.0, above the industry P\/E of 35.1. Looking ahead, growth is driven by specialty chemicals, contract manufacturing for global partners and new fluorination capacity. The company has also added capacity for products linked to battery and clean energy applications.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_Inventurus_Knowledge_Solutions_performed_financially\"><\/span><strong>How has Inventurus Knowledge Solutions performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 784 crore in FY22 to Rs 3,211 crore in FY26, a compound annual growth rate of 42.2%. Net profit grew from Rs 233 crore in FY22 to Rs 722 crore in FY26, which works out to a compound annual growth rate of 32.7%. In the June 2026 quarter, revenue grew 21.0% year on year to Rs 899 crore, while net profit rose 27.8% to Rs 194 crore. The company has a return on equity of 25.8%, a debt to equity ratio of 0.27 and a market capitalisation of Rs 29,242 crore. The stock trades at a P\/E of 38.3, above the industry P\/E of 17.6. Looking ahead, the company is widening its technology-led services for risk adjustment, care coordination and revenue cycle work. Long-term relationships with large healthcare organisations give it recurring demand.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_risks_should_investors_check_before_buying_cancer_drug_fluorine_and_health_IT_stocks\"><\/span><strong>What risks should investors check before buying cancer drug, fluorine and health IT stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Investors should check a few risks before buying cancer drug, fluorine and health IT stocks. Regulatory approvals. Plant inspections and approvals can affect supplies. Raw material and energy costs. Input prices can move margins in chemicals. Client spending. Technology budgets can vary with global conditions. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_this_list_of_cancer_drug_fluorine_and_health_IT_stocks_investment_advice\"><\/span><strong>Is this list of cancer drug, fluorine and health IT stocks investment advice?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> No. This article is educational and uses publicly available data as of the 18 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.<\/p>\n<div class=\"faq-schema\"><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"What are cancer drug, fluorine and health IT stocks?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Cancer drug, fluorine and health IT stocks are listed companies that make specialty medicines for cancer and other serious conditions, make fluorine based chemicals for cooling, batteries and drugs, and provide technology and data services to healthcare providers. Their earnings depend on medicine demand, specialty chemical orders and healthcare technology budgets. This list looks at three of them, Natco Pharma, Navin Fluorine International and Inventurus Knowledge Solutions, using reported FY22 to FY26 financials and the 18 November 2026 closing prices.\"}},{\"@type\":\"Question\",\"name\":\"Which cancer drug, fluorine and health IT stocks are covered in this list?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"This list covers Natco Pharma, Navin Fluorine International and Inventurus Knowledge Solutions. Based on the 18 November 2026 close, Natco Pharma traded at Rs 820.6, Navin Fluorine International at Rs 10,278 and Inventurus Knowledge Solutions at Rs 1,610.1. Their return on equity ranges from 15.4% to 25.8%, and their revenue compound annual growth from FY22 to FY26 ranges from 21.0% to 42.2%.\"}},{\"@type\":\"Question\",\"name\":\"Why do cancer drug, fluorine and health IT stocks have a strong future roadmap in India?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Cancer drug, fluorine and health IT stocks have a strong roadmap in India because rising demand for advanced medicines, rising demand for fluorine chemicals and wider healthcare digitisation keep widening the market for these companies. The main drivers are as follows. Specialty drugs. Patients need advanced treatments. Fluorine chemicals. Cooling and battery makers need fluorine inputs. Healthcare IT. Providers digitise their operations. Together these factors give the companies on this list a visible path for growth over the coming years.\"}},{\"@type\":\"Question\",\"name\":\"How has Natco Pharma performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 2,044 crore in FY22 to Rs 4,376 crore in FY26, a compound annual growth rate of 21.0%. Net profit grew from Rs 170 crore in FY22 to Rs 1,372 crore in FY26, which works out to a compound annual growth rate of 68.5%. The company has a return on equity of 15.4%, a debt to equity ratio of 0.08 and a market capitalisation of Rs 15,708 crore. The stock trades at a P\/E of 13.7, below the industry P\/E of 36.0. Looking ahead, the company has a track record of developing difficult-to-make generics and has built a strong position in oncology and specialty drugs. New product launches in regulated markets and investments in research support the pipeline.\"}},{\"@type\":\"Question\",\"name\":\"How has Navin Fluorine International performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 1,493 crore in FY22 to Rs 3,379 crore in FY26, a compound annual growth rate of 22.7%. Net profit grew from Rs 263 crore in FY22 to Rs 664 crore in FY26, which works out to a compound annual growth rate of 26.0%. In the June 2026 quarter, revenue grew 46.1% year on year to Rs 1,080 crore, while net profit rose 107.7% to Rs 243 crore. The company has a return on equity of 16.7%, a debt to equity ratio of 0.32 and a market capitalisation of Rs 41,847 crore. The stock trades at a P\/E of 53.0, above the industry P\/E of 35.1. Looking ahead, growth is driven by specialty chemicals, contract manufacturing for global partners and new fluorination capacity. The company has also added capacity for products linked to battery and clean energy applications.\"}},{\"@type\":\"Question\",\"name\":\"How has Inventurus Knowledge Solutions performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 784 crore in FY22 to Rs 3,211 crore in FY26, a compound annual growth rate of 42.2%. Net profit grew from Rs 233 crore in FY22 to Rs 722 crore in FY26, which works out to a compound annual growth rate of 32.7%. In the June 2026 quarter, revenue grew 21.0% year on year to Rs 899 crore, while net profit rose 27.8% to Rs 194 crore. The company has a return on equity of 25.8%, a debt to equity ratio of 0.27 and a market capitalisation of Rs 29,242 crore. The stock trades at a P\/E of 38.3, above the industry P\/E of 17.6. Looking ahead, the company is widening its technology-led services for risk adjustment, care coordination and revenue cycle work. Long-term relationships with large healthcare organisations give it recurring demand.\"}},{\"@type\":\"Question\",\"name\":\"What risks should investors check before buying cancer drug, fluorine and health IT stocks?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Investors should check a few risks before buying cancer drug, fluorine and health IT stocks. Regulatory approvals. Plant inspections and approvals can affect supplies. Raw material and energy costs. Input prices can move margins in chemicals. Client spending. Technology budgets can vary with global conditions. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.\"}},{\"@type\":\"Question\",\"name\":\"Is this list of cancer drug, fluorine and health IT stocks investment advice?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"No. This article is educational and uses publicly available data as of the 18 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.\"}}]}<\/script><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Cancer Drug, Fluorine and Health IT Stocks with a strong future roadmap: Natco Pharma, Navin Fluorine International and Inventurus Knowledge Solutions. Compare price, valuation, return on equity and revenue growth as of 17 November 2026.<\/p>\n","protected":false},"author":35,"featured_media":355366,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[845],"tags":[3803,20561,26311,26315,17146,14124,14166,26312,26313,26314],"class_list":["post-355367","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-best-stocks","tag-best-stocks","tag-cancer-drug","tag-fluorine-and-health-it-stocks","tag-fluorine-chemistry-and-healthcare-it-services-stocks","tag-inventurus-knowledge-solutions","tag-natco-pharma","tag-navin-fluorine-international","tag-oncology-generics","tag-refrigerant-inputs-and-hospital-software-shares","tag-specialty-drugs"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["355366"],"rank_math_title":["Cancer Drug, Fluorine Chemical and Health IT Stocks"],"rank_math_description":["Compare 3 cancer drug, fluorine and health IT stocks with a strong future roadmap on CMP, market cap, P\/E, ROE and revenue growth. Data as of 17 Nov 2026."],"rank_math_focus_keyword":["cancer drug, fluorine and health IT stocks"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/11\/3-oncology-medicines-firm-fluorochemicals-producer-and-hospital-software.webp","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/355367","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/35"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=355367"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/355367\/revisions"}],"predecessor-version":[{"id":355368,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/355367\/revisions\/355368"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/355366"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=355367"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=355367"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=355367"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}